Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$8.22 +2.1%	$7.06	$5.47 ▼ $11.99	$170.57M	N/A	66,840 shs	40,740 shs
IMRX Immuneering	$5.61 +8.1%	$3.78	$1.10 ▼ $6.18	$203.76M	0.37	1.25 million shs	638,143 shs
NVCT Nuvectis Pharma	$6.53 -1.8%	$7.32	$4.44 ▼ $11.80	$166.25M	-0.26	141,440 shs	55,228 shs
XFOR X4 Pharmaceuticals	$4.12 -2.6%	$2.14	$1.35 ▼ $26.83	$47.00M	0.6	1.66 million shs	589,984 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	-1.71%	+4.82%	+17.35%	-23.84%	0.00%
IMRX Immuneering	-12.33%	+51.31%	+32.74%	+206.19%	+359.29%
NVCT Nuvectis Pharma	-2.92%	+1.68%	-12.50%	-28.88%	-4.59%
XFOR X4 Pharmaceuticals	-7.64%	+51.07%	+98.59%	+20.17%	-79.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	3.54 of 5 stars	3.3	4.0	0.0	0.0	1.9	5.0	0.6
NVCT Nuvectis Pharma	3.5143 of 5 stars	3.5	3.0	0.0	0.0	2.2	5.0	0.6
XFOR X4 Pharmaceuticals	4.0389 of 5 stars	3.5	2.0	0.0	4.6	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.33	161.83% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.00	132.97% Upside
NVCT Nuvectis Pharma	3.00	Buy	$15.33	133.03% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$71.17	1,621.08% Upside

Current Analyst Ratings Breakdown

Latest XFOR, IMRX, NVCT, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	ACTU Actuate Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
8/26/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/25/2025	ACTU Actuate Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
8/18/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/14/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/13/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $3.50
8/4/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	($0.13) per share	N/A
IMRX Immuneering	$320K	633.33	N/A	N/A	$0.80 per share	6.98
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.66 per share	N/A
XFOR X4 Pharmaceuticals	$32.77M	1.44	N/A	N/A	$0.35 per share	11.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-281.83%	N/A
IMRX Immuneering	-$61.04M	-$1.89	N/A	N/A	N/A	N/A	-146.28%	-117.22%	11/12/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.17	N/A	N/A	N/A	N/A	-150.81%	-94.84%	11/4/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	-$14.84	N/A	N/A	N/A	-311.15%	-375.31%	-72.87%	11/12/2025 (Estimated)

Latest XFOR, IMRX, NVCT, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACTU Actuate Therapeutics	-$0.19	-$0.30	-$0.11	-$0.30	N/A	N/A
8/13/2025	Q2 2025	IMRX Immuneering	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/8/2025	Q2 2025	XFOR X4 Pharmaceuticals	-$4.53	-$3.47	+$1.06	-$3.47	$1.62 million	$1.97 million
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.73	0.73
IMRX Immuneering	N/A	3.70	3.70
NVCT Nuvectis Pharma	N/A	2.66	2.66
XFOR X4 Pharmaceuticals	19.10	3.19	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
IMRX Immuneering	67.65%
NVCT Nuvectis Pharma	96.77%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
IMRX Immuneering	22.90%
NVCT Nuvectis Pharma	30.52%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	20.75 million	6.36 million	N/A
IMRX Immuneering	60	36.32 million	28.00 million	Not Optionable
NVCT Nuvectis Pharma	8	25.46 million	17.69 million	Not Optionable
XFOR X4 Pharmaceuticals	80	11.41 million	11.14 million	Optionable

XFOR, IMRX, NVCT, and ACTU Headlines

Recent News About These Companies

X4 Pharmaceuticals Announces Board Resignations and Appointments

August 25 at 7:17 PM | msn.com

Brookline Capital Management Comments on XFOR Q3 Earnings

August 21, 2025 | americanbankingnews.com

Q3 EPS Forecast for X4 Pharmaceuticals Lifted by Analyst

August 17, 2025 | americanbankingnews.com

X4 Pharmaceuticals Grants Inducement Equity Awards to New Executive Officers

August 15, 2025 | quiverquant.comQ

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | globenewswire.com

X4 Pharmaceuticals Closes $85M Private Placement Deal

August 14, 2025 | theglobeandmail.com

X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright

August 13, 2025 | msn.com

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

August 13, 2025 | msn.com

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

August 13, 2025 | globenewswire.com

X4 Pharmaceuticals announces $60M financing, management changes

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60M Equity Financing

August 12, 2025 | msn.com

X4 Pharmaceuticals secures $60M PIPE financing

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

August 12, 2025 | globenewswire.com

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

X4 Pharmaceuticals Inc News (XFOR) - Investing.com

July 2, 2025 | investing.com

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR, IMRX, NVCT, and ACTU Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$8.22 +0.17 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$8.40 +0.18 (+2.24%)

As of 05:19 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Immuneering NASDAQ:IMRX

$5.61 +0.42 (+8.09%)

Closing price 04:00 PM Eastern

Extended Trading

$5.58 -0.03 (-0.45%)

As of 05:35 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$6.53 -0.12 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$6.52 0.00 (-0.08%)

As of 04:11 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

X4 Pharmaceuticals NASDAQ:XFOR

$4.12 -0.11 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$4.11 -0.01 (-0.24%)

As of 05:38 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time